Docosahexaenoic acid modulates the expression of T-bet and GATA-3 transcription factors, independently of PPARα, through suppression of MAP kinase activation

Biochimie

Volumn 91, Issue 11-12, 2009, Pages 1359-1365

  Attakpa, Eugène ^a,b   Hichami, Aziz ^b   Simonin, Anne Marie ^b   Sansón, Esther García ^a   Dramane, Karim L ^a   Khan, Naim Akhtar ^b  

^a Faculte des Sciences et Techniques   (Benin)

^b UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION REGULATION; IMMUNOMODULATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; TH1 CELL; TH2 CELL; TRANSCRIPTION REGULATION; UPREGULATION;

ANIMALS; BRONCHIAL HYPERREACTIVITY; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; DOCOSAHEXAENOIC ACIDS; DOWN-REGULATION; GATA3 TRANSCRIPTION FACTOR; INTERFERON-GAMMA; MAP KINASE SIGNALING SYSTEM; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PPAR ALPHA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; T-BOX DOMAIN PROTEINS; T-LYMPHOCYTES; TH1 CELLS; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

MUS;

EID: 73049083542     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2009.09.012     Document Type: Article

References (39)

1. Simopoulos A.P. Omega-3 fatty acids in inflammation and autoimmune diseases. J. Am. Coll. Nutr. 21 (2002) 495-505
2. Berry E.M. Dietary fatty acids in the management of diabetes mellitus. Am. J. Clin. Nutr. 66 (1997) 991S-997S
3. Khan N.A., Yessoufou A., Kim M., and Hichami A. N-3 fatty acids modulate Th1 and Th2 dichotomy in diabetic pregnancy and macrosomia. J. Autoimmun. 26 (2006) 268-277
4. Wallace F.A., Miles E.A., Evans C., Stock T.E., Yaqoob P., and Calder P.C. Dietary fatty acids influence the production of Th1- but not Th2-type cytokines. J. Leukoc. Biol. 69 (2001) 449-457
5. Kleemann R., Scott F.W., Wörz-Pagentert U., Nimal Ratnayake W.M., and Kolb H. Impact of dietary fat on Th1/Th2 cytokine gene expression in the pancreas and gut of diabetes-prone BB rats. J. Autoimmun. 11 (1998) 97-103
6. Issemann I., and Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347 (1990) 645-650
7. Wahli W. Peroxisome proliferator-activated receptors (PPARs): from metabolic control to epidermal wound healing. Swiss Med. Wkly. 132 (2002) 83-91
8. Braissant O., Foufelle F., Scotto C., Dauca M., and Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha. -beta, -gamma adult rat. Endocrinology 137 (1996) 354-366
9. Yessoufou A., Atègbo J.M., Attakpa E.S., Hichami A., Moutairou K., Dramane K.L., and Khan N.A. Peroxisome proliferator-activated receptor-alpha modulates insulin gene transcription factors and inflammation in adipose tissues in mice. Mol. Cell. Biochem. 323 (2009) 101-111
10. Issemann I., Prince R.A., Tugwood J.D., and Green S. The peroxisome proliferator-activated receptor:retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J. Mol. Endocrinol. 11 (1993) 37-47
11. Zambon A., Gervois P., Pauletto P., Fruchart J.C., and Staels B. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-{alpha} activators. Clinical and experimental evidence. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 977-986
12. Cunard R., DiCampli D., Archer D.C., Stevenson J.L., Ricote M., Glass C.K., and Kelly C.J. WY14,643, a PPAR alpha ligand, has profound effects on immune responses in vivo. J. Immunol. 169 (2002) 6806-6812
13. Lovett-Racke A.E., Hussain R.Z., Northrop S., Choy J., Rocchini A., Matthes L., Chavis J.A., Diab A., Drew P.D., and Racke M.K. Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J. Immunol. 172 (2004) 5790-5798
14. Jones D.C., Ding X., and Daynes R.A. Nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha) is expressed in resting murine lymphocytes. The PPARalpha in T and B lymphocytes is both transactivation and transrepression competent. J. Biol. Chem. 277 (2002) 6838-6845
15. Marx N., Kehrle B., Kohlhammer K., Grub M., Koenig W., Hombach V., Libby P., and Plutzky J. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ. Res. 90 (2002) 703-710
16. Raghupathy R. Pregnancy: success and failure within the Th1/Th2/Th3 paradigm. Immunology 13 (2001) 219-227
17. Gocke A.R., Hussain R.Z., Yang Y., Peng H., Weiner J., Ben L.H., Drew P.D., Stuve O., Lovett-Racke A.E., and Racke M.K. Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor-{alpha} agonists in autoimmune disease. J. Immunol. 182 (2009) 4479-4487
18. Dasgupta S., Roy A., Jana M., Hartley D.M., and Pahan K. Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-alpha. Mol. Pharmacol. 72 (2007) 934-946
19. Lee S.S., Pineau T., Drago J., Lee E.J., Owens J.W., Kroetz D.L., Fernandez-Salguero P.M., Westphal H., and Gonzalez F.J. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 15 (1995) 3012-3022
20. Spencer N.F.L., Norton S.D., Harrison L.L., Li G.Z., and Daynes R.A. Dysregulation of IL-10 production with aging: possible linkage to the age-associated decline in DHEA and its sulfated derivative. Exp. Gerontol. 31 (1996) 393
21. Das J., Chen C.H., Yang L., Cohn L., Ray P., and Ray A. A critical role for NF-κB in GATA3 expression and TH2 differentiation in allergic airway inflammation. Nat. Immunol. 2 (2001) 45
22. Denys A., Hichami A., and Khan N.A. n-3 PUFAs modulate T-cell activation via protein kinase C-alpha and -epsilon and the NF-kappaB signaling pathway. J. Lipid Res. 46 (2005) 752-758
23. Kremer J.M., Lawrence D.A., Jubiz W., DiGiacomo R., Rynes R., Bartholomew L.E., and Sherman M. Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects. Arthritis Rheum. 33 (1990) 810-820
24. Bittiner S.B., Tucker W.F., Cartwright I., and Bleehen S.S. A double-blind, randomised, placebo-controlled trial of fish oil in psoriasis. Lancet 1 (1988) 378-380
25. Bjorneboe A., Soyland E., Bjorneboe G.E., Rajka G., and Drevon C.A. Effect of dietary supplementation with eicosapentaenoic acid in the treatment of atopic dermatitis. Br. J. Dermatol. 117 (1987) 463-469
26. Ho I.C., and Glimcher L.H. Transcription: tantalizing times for T cells. Cell 109 (2002) S109
27. Szabo S.J., Kim S.T., Costa G.L., Zhang X., Fathman C.G., and Glimcher L.H. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100 (2000) 655
28. Yamashita M., Ukai-Tadenuma M., Miyamoto T., Sugaya K., Hosokawa H., Hasegawa A., Kimura M., Taniguchi M., DeGregori J., and Nakayama T. Essential role of GATA3 for the maintenance of type 2 helper T (Th2) cytokine production and chromatin remodeling at the Th2 cytokine gene loci. J. Biol. Chem. 279 (2004) 26983-26990
29. Lighvani A.A., Frucht D.M., Jankovic D., Yamane H., Aliberti J., Hissong B.D., Nguyen B.V., Gadina M., Sher A., Paul W.E., and O'Shea J.J. T-bet is rapidly induced by interferon-γ in lymphoid and myeloid cells. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 15137
30. Napolitani G., Acosta-Rodriguez E.V., Lanzavecchia A., and Sallusto F. Prostaglandin E2 enhances Th17 responses via modulation of IL-17 and IFN-gamma production by memory CD4+ T cells. Eur. J. Immunol. 39 (2009) 1301-1312
31. Denys A., Hichami A., and Khan N.A. Eicosapentaenoic acid and docosahexaenoic acid modulate MAP kinase (ERK1/ERK2) signaling in human T cells. J. Lipid Res. 42 (2001) 2015-2020
32. Denys A., Aires V., Hichami A., and Khan N.A. Thapsigargin-stimulated MAP kinase phosphorylation via CRAC channels and PLD activation: inhibitory action of docosahexaenoic acid. FEBS Lett. 564 (2004) 177-182
33. Khan N.A., Nishimura K., Aires V., Yamashita T., Oaxaca-Castillo D., Kashiwagi K., and Igarashi K. Docosahexaenoic acid inhibits growth of mouse mammary cancer cells by interfering with p27/kip1, Cdk2, ERK1/ERK2 and retinoblastoma phosphorylation. J. Lipid Res. 47 (2006) 2306-2313
34. 1. J. Immunol. 171 (2003) 196-203
35. Rincon M., Enslen H., Raingeaud J., Recht M., Zapton T., Su M.S., Penix L.A., Davis R.J., and Flavell R.A. Interferon-γ expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. EMBO J. 17 (1998) 2817
36. Lu B., Yu H., Chow C., Li B., Zheng W., Davis R.J., and Flavell R.A. GADD45γ mediates the activation of the p38 and JNK MAP kinase pathways and cytokine production in effector TH1 cells. Immunity 14 (2001) 583
37. Guillot N., Caillet E., Laville M., Calzada C., Lagarde M., and Véricel E. Increasing intakes of the long-chain ω-3 docosahexaenoic acid: effects on platelet functions and redox status in healthy men. FASEB J. (2009) May 14. [Epub ahead of print]
38. Owaki T., Asakawa M., Fukai F., Mizuguchi J., and Yoshimoto T. IL-27 induces Th1 differentiation via p38 MAPK/T-bet- and intercellular adhesion molecule-1/LFA-1/ERK1/2-dependent pathways. J. Immunol. 177 (2006) 7579-7587
39. Bachmann M., Dragoi C., Poleganov M.A., Pfeilschifter J., and Mühl H. Interleukin-18 directly activates T-bet expression and function via p38 mitogen-activated protein kinase and nuclear factor-kappaB in acute myeloid leukemia-derived predendritic KG-1 cells. Mol. Cancer Ther. 6 (2007) 723-731